SCHEMBL19274530

SCHEMBL19274530

NCc1ccc([S+]([O-])c2cccc(-c3ccccc3)c2)s1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 3/20 0.49
CYP3A4 P08684 3/20 0.49
CYP2A6 P11509 3/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2B6 P20813 3/20 0.49
CYP2C19 P33261 3/20 0.49
LOX P28300 7/20 0.46
LOXL2 Q9Y4K0 11/20 0.40
CYP2D6 P10635 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C8 P10632 1/20 0.37
LOXL3 P58215 1/20 0.37
KCNH2 Q12809 1/20 0.37
AOC3 Q16853 1/20 0.37
TAAR1 Q96RJ0 1/20 0.36
MAOA P21397 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19259658 0.86 CYP2A6 (0.46) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL19274428 0.78 LOXL2 (0.48) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL19274690 0.74 CYP2E1 (0.38) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL11281313 0.74 MAOA (0.44) CYP3A4CYP2C9MAOA
SCHEMBL28741356 0.72 MAOA (0.43) CYP3A4CYP2C9MAOA
SCHEMBL19274370 0.71 CYP2E1 (0.33) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL19274429 0.68 LOX (0.31) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL23569386 0.67 MAOA (0.46) CYP3A4TAAR1MAOA
SCHEMBL2690207 0.67 CYP2E1 (1.00) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL20048800 0.67 MAOA (0.46) CYP3A4TAAR1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017141049-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2017-08-24 WO disclosed